公开(公告)号：WO1994005289A1

公开(公告)日：1994-03-17

申请号：PCT/US1993008527

申请日：1993-09-09

Applicant: VANDERBILT UNIVERSITY

Inventor： VANDERBILT UNIVERSITY ,  KON, Valentina ,  FOGO, Agnes ,  ICHIKAWA, Iekuni

IPC: A61K31/44

CPC classification number: A61K31/44 ,  A61K31/00 ,  A61K31/4178 ,  A61K31/437 ,  A61K31/4439

Abstract: This invention provides a method of and compositions for increasing or maintaining glomerular filtration rate while preserving renal structure in a patient comprising administering an angiotensin II type 1 vascular receptor antagonist to the patient, independent of its effects on systemic blood pressure. The invention provides that, by administering the AII type 1 receptor antagonist, blood flow to the kidney can be improved without sacrificing intraglomerular pressure and therefore glomerular filtration and that even with this enhanced glomerular pressure and filtration, renal structure is preserved. Also provided is a method of screening AII type 1 receptor antagonists for the ability to maintain or increase glomerular filtration rate while decreasing mesangial matrix accumulation comprising the steps of administering the antagonist in an animal model characterized by decreased glomerular filtration rate and increased mesangial matrix accumulation and selecting the compounds that increase glomerular filtration rate while decreasing mesangial matrix accumulation.

Abstract translation: 本发明提供了一种用于增加或维持肾小球滤过率同时保持患者肾结构的方法和组合物，包括向患者施用血管紧张素II 1型血管受体拮抗剂，而不受其对全身血压的影响。 本发明提供了通过施用AII 1型受体拮抗剂，可以改善血液流向肾脏，而不会牺牲肾小球内的压力，因此肾小球滤过，即使用这种增强的肾小球压力和过滤也可保持肾结构。 还提供了筛选AII 1型受体拮抗剂以减少肾小球滤过率同时减少肾小球系膜基质蓄积的能力的方法，其包括在动物模型中施用拮抗剂的步骤，其特征在于肾小球滤过率降低和肾小球系膜基质积累增加， 选择增加肾小球滤过率同时减少肾小球系膜基质积累的化合物。

公开(公告)号：WO1993012875A1

公开(公告)日：1993-07-08

申请号：PCT/US1992009781

申请日：1992-11-19

Applicant: VANDERBILT UNIVERSITY

Inventor： VANDERBILT UNIVERSITY ,  WANG, Taylor, Gun-Jin

IPC: B01J13/04

CPC classification number: C12N11/04 ,  A61K9/1694 ,  B01J13/04 ,  B29B9/00 ,  B29B9/12 ,  Y10T428/2984

Abstract: The present invention relates to a method and apparatus for producing uniform polymeric spheres with controllable permeability. This invention may be useful for encapsulating living cells or tissue or chemicals or medicines in uniform polymeric spheres. In particular, this invention relates to polymeric microspheres made from polycation and polyanion polymer solutions. An apparatus includes airtight housing (1) having top (3) and bottom (25) chambers. Top chamber (3) includes pressure regulator means (5), stationary polyanion reservoir tank (7), polycation reservoir tank (27), and feed line (9) to adjustable tank (11). Tank (11) is associated with oscillator (13), nozzle (14) and capacitance means (19). Nozzle (14) and oscillator (3) cooperate to form polyanion droplets. In the bottom chamber (25) annular nozzle (50) is used to form an annular jet of polycation solution. The droplets and polycation jet are mixed at minimal impact velocities to form uniform polymeric sphere.

公开(公告)号：WO1993008803A1

公开(公告)日：1993-05-13

申请号：PCT/US1992008916

申请日：1992-10-16

Applicant: BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY ,  VANDERBILT UNIVERSITY

Inventor： BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY ,  VANDERBILT UNIVERSITY ,  HONN, Kenneth, V. ,  JOHNSON, Carl, R. ,  CHEN, Yung-Fa ,  SHIMOJI, Katsu-ichi ,  MARNETT, Lawrence, J.

IPC: A61K31/445

CPC classification number: C07D211/94

Abstract: Novel cyclic hydroxamic acid of formula (I), R?1, R2, and R3¿ each, independently, is hydrogen, C1-24 alkyl, C2-24 alkenyl or an aryl or arylalkyl group of formulae (a), (b), (c), (d), wherein R?4, R5, R7 and R8¿ each, independently is hydrogen, C1-4 alkyl, C1-4 alkoxy, trifluoromethyl, halogen or nitro; l is 1-3; m is 1-3; n is 1-3; k is 1-3; R?6 and R9¿ each, independently is C1-24 alkylene or C2-24 alkenylene; wherein at least one R?1, R2 and R3¿ is selected from the group consisting of aryl and arylalkyl and wherein at least one other R?1, R2 and R3¿ is selected from the group consisting of alkyl, alkenyl, aryl and arylalkyl; with the provisos that, more than one of R?1, R2 and R3¿ are not hydrogen at the same time and that at least two substituents other than hydrogen of the R?1, R2 and R3¿ substituents are found at different carbons of the piperidin-2-one ring; and the pharmaceutically acceptable salts thereof possess an inhibitory activity against 12-lipoxygenase, and therefore, may be useful for treating and/or preventing inflammation, immune diseases, psoriasis, arteriosclerosis and/or ischaemic cardiovascular diseases and also for suppressing metastasis of cancer.

公开(公告)号：WO1993000445A1

公开(公告)日：1993-01-07

申请号：PCT/US1992004764

申请日：1992-06-04

Applicant: VANDERBILT UNIVERSITY

Inventor： VANDERBILT UNIVERSITY ,  PHILLIPS, John, A., III ,  VNENCAK-JONES, Cindy, L.

IPC: C12Q01/68

CPC classification number: C12Q1/6858 ,  C12Q1/6827 ,  C12Q1/683 ,  C12Q1/6853 ,  C12Q1/6883 ,  C12Q2600/156

Abstract: A method of detecting gene deletions includes the steps of obtaining a genomic DNA sample possibly including a gene deletion, the gene having two ends normally flanked by two homologous regions having substantially identical portions, the gene deletion being in the form of a fusion fragment of the two homologous regions. The genomic DNA is amplified using a set of primers capable of amplifying both the fusion fragment and the two normal homologous regions having the gene in-between. The amplified fusion fragments are characterized alone indicating a homozygous deletion, a combination of fusion fragments and the two homologous regions and the gene in-between indicating a heterozygote deletion, or the two homologous regions and the gene alone indicating a homozygous nondeletion. Novel primers for use in the inventive method are also disclosed.

Abstract translation: 一种检测基因缺失的方法包括以下步骤：获得可能包含基因缺失的基因组DNA样品，所述基因具有两个通常侧翼于两个基本上相同部分的同源区的两个末端，所述基因缺失为 两个同源区。 使用能够扩增融合片段和两个具有该基因的两个正常同源区的引物进行基因组DNA的扩增。 单独表征扩增的融合片段，表明纯合缺失，融合片段和两个同源区域的组合以及表达杂合子缺失的两者之间的基因，或两个同源区域和单独的基因，表明纯合无缺失突变。 还公开了用于本发明方法的新型引物。

公开(公告)号：WO1992020346A1

公开(公告)日：1992-11-26

申请号：PCT/US1992002528

申请日：1992-03-26

Applicant: VANDERBILT UNIVERSITY

Inventor： VANDERBILT UNIVERSITY ,  FORMAN, Mervyn, B. ,  JACKSON, Edwin, K.

IPC: A61K31/70

CPC classification number: A61K31/70 ,  A61K31/165 ,  A61K2300/00

Abstract: This invention relates to a method to treat a heart attack victim to reduce heart muscle damage. In particular, the invention relates to a method to reduce myocardial reperfusion injury by selectively administering a nonhypotensive amount of a compound that selectively activates adenosine-1 receptor, a compound that selectively activates adenosine-2 receptor, or an adenosine, all in the presence of an effective amount of lidocaine.

公开(公告)号：WO1992019730A1

公开(公告)日：1992-11-12

申请号：PCT/US1992002465

申请日：1992-03-27

Applicant: VANDERBILT UNIVERSITY

Inventor： VANDERBILT UNIVERSITY ,  BRIGHAM, Kenneth ,  CONARY, Jon ,  CANONICO, Angelo ,  MEYRICK, Barbara

IPC: C12N15/00

CPC classification number: C12N15/85 ,  C07K14/8125

Abstract: A plasmid consists essentially of a small pCMV4 expression vector including a coding sequence of human alpha-1 antitrypsin incorporated therein. The present invention further provides a method for delivering the gene to a patient, the mechanism including a liposome including the expression plasmid incorporated therein, the plasmid being capable of expression of the gene extrachromosomally in the cells of a target tissue and being unincorporable into the chromosome of the cells of the target tissue. The present invention further provides a primer for inserting the coding sequence of the protein into the expression vector. Finally, the present invention provides a method of treatment for deficiency of a gene product in cells of a target tissue by using the novel liposome.

Abstract translation: 质粒基本上由包含其中结合有人α-1抗胰蛋白酶的编码序列的小pCMV4表达载体组成。 本发明还提供了将基因递送至患者的方法，所述方法包括包含其中并入的表达质粒的脂质体，所述质粒能够在靶组织的细胞中染色体外表达基因，并且不能并入染色体 的靶组织的细胞。 本发明还提供了用于将蛋白质的编码序列插入到表达载体中的引物。 最后，本发明提供了通过使用新的脂质体来治疗目标组织的细胞中的基因产物的缺陷的方法。

公开(公告)号：WO1988001291A1

公开(公告)日：1988-02-25

申请号：PCT/US1987001940

申请日：1987-08-07

Applicant: VANDERBILT UNIVERSITY

Inventor： VANDERBILT UNIVERSITY ,  TIBBETTS, Clark ,  LARSEN, Pamela, L. ,  JONES, Stephen, N. ,  McGRANE, Mary, M.

IPC: C12N05/00

CPC classification number: C12N15/85

Abstract: A novel alteration of a viral DNA sequence, derived from a human adenovirus type 3 mutant (Ad3) designated Ad3h15, provides a transcriptional control element which can be used to regulate expression of a selected gene in animal and human cells. The Ad3h15 control element blocks transcription of a controlled gene in the presence of the products of the Ad3 E1A gene, and amplifies transcription in the presence of type 5 (Ad5) adenovirus E1A gene products.

公开(公告)号：WO1998029382A1

公开(公告)日：1998-07-09

申请号：PCT/US1997024203

申请日：1997-12-30

Applicant: VANDERBILT UNIVERSITY

Inventor： VANDERBILT UNIVERSITY ,  MARNETT, Lawrence, J. ,  KALGUTKAR, Amit, S.

IPC: C07C205/00

CPC classification number: C07C323/20

Abstract: The present invention provides a compound of formula (I), wherein R is selected from the group consisting of CH3, CH2CH3, (CH2)2CH3, (CH2)3CH3, (CH2)4CH3, (CH2)5CH3, (CH2)6CH3, (CH2)2O(CH2)3CH3, CH2HC=CH(CH2)3CH3, CH2CC(CH2)3CH3, CCH2CC(CH2)2CH3, CH2CC-CCH2CH3, CH2CC-CH3 and CH2CCH; and R' is selected from the group consisting of CH3, CF3, CH2Cl and CH2Br or a pharmaceutically acceptable salt or hydrate thereof. Also provided is a method of inhibiting the synthesis of prostaglandin endoperoxide syntase-2 (PGHS-2) in a mammal.

Abstract translation: 本发明提供式（I）化合物，其中R选自CH3，CH2CH3，（CH2）2CH3，（CH2）3CH3，（CH2）4CH3，（CH2）5CH3，（CH2）6CH3， （CH2）2O（CH2）3CH3，CH2HC = CH（CH2）3CH3，CH2CC（CH2）3CH3，CCH2CC（CH2）2CH3，CH2CC-CCH2CH3，CH2CC-CH3和CH2CCH; 并且R'选自CH 3，CF 3，CH 2 Cl和CH 2 Br或其药学上可接受的盐或水合物。 还提供了抑制哺乳动物中前列腺素内过氧化物合成酶-2（PGHS-2）的合成的方法。

公开(公告)号：WO1998016241A1

公开(公告)日：1998-04-23

申请号：PCT/US1997018331

申请日：1997-10-09

Applicant: VANDERBILT UNIVERSITY ,  HAWIGER, Jack, J. ,  TIMMONS, Sheila ,  LIU, Xue-Yan

Inventor： VANDERBILT UNIVERSITY

IPC: A61K38/10

CPC classification number: C07K14/70557 ,  A61K38/17 ,  C07K14/7055 ,  C07K14/70553 ,  A61K38/13 ,  A61K31/275 ,  A61K2300/00

Abstract: The present invention provides a method of inhibiting or disrupting cellular adhesion of a cell comprising transferring into the cell a polypeptide comprising a cell adhesion regulatory domain of an adhesion receptor or counter receptor expressed by the cell. In particular, the present invention provides a method of inhibiting or disrupting cellular adhesion of a cell comprising transferring into the cell a polypeptide comprising a cell adhesion regulatory domain of a subunit, i.e., the alpha subunit or the beta subunit of an integrin expressed by the cell.

Abstract translation: 本发明提供了抑制或破坏细胞的细胞粘附的方法，其包括向细胞转移包含由细胞表达的粘附受体或反应受体的细胞粘附调节结构域的多肽。 特别地，本发明提供了抑制或破坏细胞细胞粘附的方法，其包括向细胞转移包含亚单位的细胞粘附调节结构域的多肽，即由亚单位表达的整合素的α亚基或β亚单位 细胞。

公开(公告)号：WO1998014603A1

公开(公告)日：1998-04-09

申请号：PCT/US1997017535

申请日：1997-09-30

Applicant: VANDERBILT UNIVERSITY ,  HELLERQVIST, Carl, G.

Inventor： VANDERBILT UNIVERSITY

IPC: C12P19/26

CPC classification number: C12P19/26 ,  C12P1/04 ,  C12R1/46

Abstract: A method for purifying a polysaccharide from group B beta -hemolytic Streptococcus (GBS) bacteria includes contacting a bacterial fermentation stock with a hydrophobic interaction chromatography (HIC) resin. Additional steps may include a phenol/saline extraction and an ion exchange chromatography. The method results in a product having very high purity. The product of the purification provides a composition which is highly useful in both research and therapeutic settings.

Abstract translation: 从B组β-溶血性链球菌（GBS）细菌中纯化多糖的方法包括使细菌发酵原料与疏水相互作用层析（HIC）树脂接触。 附加步骤可以包括苯酚/盐水萃取和离子交换层析。 该方法产生具有非常高纯度的产物。 纯化的产物提供了在研究和治疗环境中非常有用的组合物。